THE BUSINESS OF LONGEVITY – Chapter SevenWho Really Owns Wellbeing?

Following the Ownership, Control and Money Behind the Foundation

There is one question that sits at the centre of almost every serious corporate investigation.

Who ultimately owns the business?

It sounds simple.

Often, it isn't.

A company's website may identify its chairman, chief executive, scientists and advisers.

Corporate announcements may discuss investment, expansion and future plans.

But management and ownership are two entirely different things.

Directors run companies.

Shareholders own them.

And when multiple companies, jurisdictions and investment arrangements become involved, establishing where ultimate ownership and economic control actually sit can become considerably more difficult.

That is where this investigation now turns.

Leadership Is Not Ownership

Wellbeing International Foundation publicly identifies the people responsible for leading its organisation.

We have already examined some of that leadership in previous chapters.

But knowing who manages a business does not answer several fundamental questions:

Who are the shareholders?

Who holds voting control?

Who provided the investment capital?

Who owns the intellectual property?

Who ultimately benefits financially if the company becomes enormously successful?

For anyone considering an investment, these would normally be basic due-diligence questions.

For the public attempting to understand Wellbeing, the answers are much less obvious.

A Foundation – But Who Owns It?

The name itself remains interesting.

Wellbeing International Foundation.

As discussed previously, the word Foundation can naturally create associations with charitable, philanthropic or academic organisations.

But a name does not determine a corporate structure.

Wellbeing's own public communications discuss private investment, patient revenue, international expansion and commercial development.

That makes understanding ownership particularly important.

If private investors participate financially in the organisation, what exactly have they invested in?

Equity?

Debt?

Convertible instruments?

Another investment vehicle?

And which legal entity issued that investment?

These questions cannot be answered simply by reading the organisation's website.

The 2026 Investment Round

Wellbeing publicly announced that it had closed the first tranche of its 2026 investment round.

This was clearly considered an important milestone.

Capital would support continued development and expansion.

What remains absent from the public announcement is equally interesting.

The company did not publicly identify:

• the amount raised;

• the valuation;

• participating investors;

• the percentage of the company sold;

• the securities issued;

• the voting rights attached to them;

• the resulting ownership structure.

Again, private companies frequently keep investment terms confidential.

That is not evidence of anything improper.

But it means outsiders cannot independently determine something extremely important:

Who owns the company after the investment round?

Follow the Economic Interest

Corporate ownership is not always as straightforward as finding a shareholder's name.

Control can exist through several mechanisms.

Voting shares.

Preference shares.

Holding companies.

Convertible debt.

Licensing arrangements.

Shareholder agreements.

Intellectual-property ownership.

Sometimes the company generating revenue is not the company holding the most valuable assets.

That is why serious due diligence follows more than the money.

It follows the economic interest.

Who Owns the Science?

This leads directly back to the reason this investigation began.

Cell-Free Therapy.

If Wellbeing's technology eventually proves commercially successful, the intellectual property surrounding it could potentially become extremely valuable.

But who owns it?

The scientists?

Wellbeing International Foundation?

A related company?

An intellectual-property holding vehicle?

Private investors?

Or some combination of these?

The answer matters.

Because owning a healthcare operation and owning the intellectual property used by that operation are not necessarily the same thing.

A clinic might generate patient revenue while paying another company for access to technology.

A research company might develop intellectual property subsequently licensed internationally.

A holding company might own both.

All are perfectly conventional structures.

But until the relationships are established, we should not assume which structure applies here.

Patient Money and Investor Money

Another question deserves attention.

Wellbeing has acknowledged a business model involving patient revenue alongside private investment.

Those are two fundamentally different sources of capital.

Patients pay for services.

Investors provide money expecting some form of economic return.

Understanding where those two streams enter the corporate structure would provide important insight into how the organisation operates.

Which entity invoices patients?

Which company pays for research?

Which company employs researchers?

Which entity owns laboratory relationships?

Which company received investor capital?

Where are profits ultimately retained?

At present, the publicly available information does not provide a sufficiently complete picture to answer all of those questions confidently.

That absence should not be filled with speculation.

It should be filled with documents.

Bermuda Becomes Important Again

This brings us back to Bermuda.

The significance of Bermuda is not that it is an offshore jurisdiction.

That description alone tells us very little.

The significance is that the level of publicly accessible corporate information differs from jurisdictions such as the United Kingdom.

This creates a practical challenge for anyone trying to reconstruct ultimate ownership using public records alone.

Information may exist within corporate registers, company books, shareholder agreements and regulatory filings without all of it being freely available to the public.

Therefore, the responsible conclusion is not:

"The ownership is being hidden."

The responsible conclusion is:

"The ultimate ownership cannot yet be established from the public information we have examined."

Those statements mean very different things.

And investigative journalism must understand the difference.

Why Ownership Matters to Investors

Imagine being offered an investment in an emerging longevity company.

Before investing, most experienced investors would want answers to basic questions.

What exactly am I buying?

What percentage will I own?

What valuation am I investing at?

Who are the existing shareholders?

Who has voting control?

Where is the intellectual property?

What happens if further capital is raised?

What is my exit?

Those questions have nothing specifically to do with stem cells.

They are Investment 101.

The interesting question is therefore what information prospective investors in Wellbeing receive privately that remains unavailable publicly.

There may well be extensive investment documentation answering every one of these questions.

If so, examining that material would significantly advance this investigation.

And Why It Matters to Patients

Patients might reasonably ask:

Why should I care who owns the company?

Because ownership can influence priorities.

An organisation funded primarily through philanthropy may operate differently from one funded by venture capital.

A founder-controlled research company may behave differently from one controlled by external investors.

Neither model is inherently better.

But they have different incentives.

Understanding those incentives helps people understand the organisation with which they are dealing.

What We Know – and What We Don't

At this stage, it is important to draw a line between established facts and unanswered questions.

We know that Wellbeing operates commercially.

We know that it receives patient revenue.

We know that private investment has been raised.

We know that international expansion forms part of its strategy.

We know that scientific research has become an increasingly important part of its public credibility.

What we do not yet have is a complete independently verified picture of:

• ultimate beneficial ownership;

• shareholder percentages;

• voting control;

• the investment-round valuation;

• the amount invested;

• the investment instruments;

• ownership of the core intellectual property;

• the movement of money between relevant entities.

That distinction is crucial.

Missing information is not evidence of misconduct.

But missing information is precisely where an investigation should look next.

The Investment Proposition

This investigation began with a medical question.

Does the treatment work?

It then became a scientific question.

What does the research actually prove?

Then came the corporate question.

How is Wellbeing structured?

We have now reached the financial question.

What exactly are investors being asked to invest in?

That may ultimately become one of the most important questions in this entire investigation.

Because an experimental medical programme and an investment proposition operate according to completely different standards.

Science asks whether something works.

Investment asks what something might someday be worth.

Between those two questions exists an enormous space occupied by expectation, risk and opportunity.

And sometimes, extraordinary amounts of money.

Looking Ahead

The next stage of this investigation will therefore follow the investment itself.

Not the announcement.

The proposition.

What is being offered?

How is the company valued?

What projections are being made?

What scientific claims appear in investor materials?

What risks are disclosed?

And perhaps most importantly:

Does the story being presented to investors accurately reflect what the scientific evidence currently supports?

That comparison could tell us more about the Business of Longevity than anything we have discovered so far.

Because when emerging science becomes an investment opportunity, there are suddenly two products being evaluated.

The treatment being offered to patients.

And the future being sold to investors.